Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | BMP1 | P13497 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.46 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.46 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 4/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | GNPAT | O15228 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1854118 | 1.00 | KMT2A (0.48) | KMT2AALOX15BLMPMP22BMP1 | |
| SCHEMBL29517657 | 1.00 | KMT2A (0.48) | KMT2AALOX15BLMPMP22BMP1 | |
| SCHEMBL27753549 | 0.98 | KMT2A (0.47) | KMT2AALOX15BLMPMP22BMP1 | |
| SCHEMBL5970329 | 0.92 | KMT2A (0.50) | KMT2AALOX15BLMPMP22BMP1 | |
| SCHEMBL5970326 | 0.92 | KMT2A (0.50) | KMT2AALOX15BLMPMP22BMP1 | |
| SCHEMBL30717261 | 0.91 | BACE1 (0.45) | KMT2AALOX15BLMPMP22BMP1 | |
| SCHEMBL30760990 | 0.90 | FOLH1 (0.58) | BMP1FOLH1RIMKLANAALAD2DPP4 | |
| SCHEMBL10165828 | 0.90 | FOLH1 (0.58) | BMP1FOLH1RIMKLANAALAD2DPP4 | |
| SCHEMBL27599412 | 0.90 | FOLH1 (0.58) | BMP1FOLH1RIMKLANAALAD2DPP4 | |
| SCHEMBL1276949 | 0.90 | FOLH1 (0.58) | BMP1FOLH1RIMKLANAALAD2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720303-A2 | COMPOSITIONS AND METHODS FOR EXPRESSION OF IL-1RA AND IL-18BP | Replicate Bioscience, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| WO-2025245292-A1 | NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USES THEREOF FOR MODULATING WEIGHT LOSS | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| WO-2025245294-A1 | NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USES THEREOF FOR MODULATING WEIGHT GAIN | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| WO-2025123055-A1 | NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS AND ASSOCIATED METHODS FOR MODULATING WEIGHT GAIN | ENDEVICA BIO, INC. (US) | 2025-06-12 | — | — | WO | claimed |
| WO-2025123059-A1 | NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS AND USES THEREOF FOR TREATING SUBSTANCE USE DISORDERS | ENDEVICA BIO, INC. (US) | 2025-06-12 | — | — | WO | claimed |
| WO-2025123051-A1 | NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS AND USES THEREOF FOR MODULATING WEIGHT GAIN | ENDEVICA BIO, INC. (US) | 2025-06-12 | — | — | WO | claimed |
| WO-2024249263-A2 | COMPOSITIONS AND METHODS FOR EXPRESSION OF IL-1RA AND IL-18BP | REPLICATE BIOSCIENCE, INC. (US) | 2024-12-05 | — | — | WO | claimed |
| CN-118660707-A | Supermolecule self-assembly system | 北京睿创康泰医药研究院有限公司 | 2024-09-17 | — | — | CN | claimed |
| WO-2024163874-A2 | STABLE AND CONTROLLED RELEASE FORMULATIONS OF NEUREGULIN-4 ANALOGS | AVEXEGEN THERAPEUTICS, INC. (US) | 2024-08-08 | — | — | WO | claimed |
| WO-2023193244-A1 | SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM | 北京睿创康泰医药研究院有限公司 | 2023-10-12 | — | — | WO | claimed |
| WO-2023150693-A2 | NEUREGULIN-4 ANALOGS AND METHODS OF USING THEREOF IN DISEASE TREATMENT | AVEXEGEN THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | WO | claimed |
| US-20190033313-A1 | METHODS AND SYSTEMS FOR DETECTING MELANOMA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2019-01-31 | — | — | US | claimed |
| EP-2323693-B1 | DRUG CARRIERS | NITTO DENKO CORP (JP) | 2017-11-08 | — | — | EP | claimed |
| WO-2016196743-A1 | METHODS AND SYSTEMS FOR DETECTING MELANOMA | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2016-12-08 | — | — | WO | claimed |
| WO-2011133617-A1 | NANO-HYBRID DELIVERY SYSTEM FOR SEQUENTIAL UTILIZATION OF PASSIVE AND ACTIVE TARGETING | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-10-27 | — | — | WO | claimed |
| EP-0512435-B1 | Method of crystallizing aspartame | AJINOMOTO KK (JP) | 1997-01-22 | — | — | EP | claimed |
| US-5298648-A | Method of crystallizing aspartame | AJINOMOTO CO., INC. (JP) | 1994-03-29 | — | — | US | claimed |
| JP-62151156-A | — | — | None | — | — | JP | disclosed |
| EP-0131477-B1 | USE OF A SALT OF THE ACID N-ACETYL (ALPHA, BETA) ASPARTYLGLUTAMIC FOR THE MANUFACTURE OF A DRUG HAVING AN ANTI-ALLERGIC ACTIVITY FOR LOCAL ADMINISTRATION | THEA (Thérapeutique et Applications) S.A. (FR) | 1987-06-24 | — | — | EP | disclosed |
| EP-0131477-A1 | Use of a salt of the acid N-acetyl (alpha, beta) aspartylglutamic for the manufacture of a drug having an anti-allergic activity for local administration | THEA (Thérapeutique et Applications) S.A. (FR) | 1985-01-16 | — | — | EP | disclosed |